COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological

Related Keywords

United Kingdom ,London ,City Of ,Anna Keski Rahkonen ,Isabelle Jaussent ,Paul Liknaitzky ,Hans Wijbrand Hoek ,Clairej Foldi ,Philippe Courtet ,Martin Williams ,Stephanie Knatz Peck ,Stephen Schultz ,Amy Lawrence ,Sheppard Pratt ,Jon Arcelus ,Walterh Kaye ,Jackie Wales ,Walter Kaye ,Ulrike Schmidt ,Alexj Mitchell ,Columbia University Irving Medical Center ,Exchange Commission ,Linkedin ,Us King College London ,Department Of Psychiatry ,Nasdaq ,College London ,California San Diego School ,Eating Disorder Examination ,Medicine Department ,Psychiatry Eating Disorders Program ,Principal Investigator ,Guy Goodwin ,Chief Medical Officer ,Securities Act ,Private Securities Litigation Reform Act ,Therapeutic Strategies ,Anorexia Nervosa ,Insights From Psychedelic Medicine ,Animal Models ,Suicide Attempts ,Bulimia Nervosa ,Case Control Study ,Emilie Oli ,Catherine Genty ,Jacques Bringer ,Anu Raevuori ,Hans Wijbrand ,Stephanie Knatz Peck Phd ,Samantha Shao ,Susan Murray Phd ,Compass ,Pathways ,Aunches ,Hase ,Linical ,Trial ,Silocybin ,Therapy ,Anorexia ,Nervosa ,